Bausch + Lomb Secures CE Mark for Compact Femtosecond Laser — Bausch + Lomb Corporation

Event summary

Bausch + Lomb received European CE Mark approval for SeeLyra, a next-generation femtosecond laser platform.
SeeLyra is designed for precision in cataract, LASIK flap, and corneal therapeutic surgeries with a compact, flexible design.
The laser features live swept source OCT for real-time depth-visualization and retains key features of the previous VICTUS platform.
Limited availability in Europe begins in late 2026, with broader rollout expected in 2027.
Bausch + Lomb is seeking regulatory approvals for SeeLyra in other markets, including the United States.

The big picture

Bausch + Lomb's CE Mark approval for SeeLyra positions the company to capitalize on the growing demand for precision surgical tools in ophthalmology. The compact and flexible design of SeeLyra addresses the needs of modern ORs, potentially expanding the company's footprint in the premium cataract and LASIK markets. The strategic move underscores Bausch + Lomb's commitment to innovation in eye health, aiming to enhance surgical outcomes and operational efficiency.

What we're watching

Regulatory Approval: The pace at which Bausch + Lomb secures approvals in other markets, particularly the United States, will determine the global rollout timeline for SeeLyra.
Market Adoption: Whether SeeLyra can gain traction among surgeons and ORs, given its compact design and advanced features, will be critical for its success.
Competitive Positioning: How SeeLyra differentiates itself from existing platforms like VICTUS and other competitors in the femtosecond laser market.